Foundation Medicine’s Post

Breast cancer is the most common cancer in the UK. October is Breast Cancer Awareness Month, which is dedicated to educating, raising awareness and supporting patients with breast cancer. At Inaphaea, we offer cells for purchase and testing services across our biobank of 470 Patient Derived Cancer cells, representing 66 types of cancer, including 23 breast cancer subtypes of which 3 are Triple Negative Breast Cancer. We are dedicated to comprehensively understanding our drug candidates during the discovery and preclinical phases of development to address the unique challenges of each subtype. Our goal is to support decision-making in translational drug development for therapeutic areas within oncology. View more on our website: https://bit.ly/3SINi9o #CancerResearch #DrugDevelopment #CancerAwareness #DrugDiscovery

Caris and collaborators from leading cancer centers, including those within the Caris Precision Oncology Alliance™ (Caris POA), will collectively present seven studies across a range of breast cancer types, including male breast cancer, at the San Antonio Breast Cancer Symposium (SABCS). “Our vast real-world evidence from over 748,000 cases, including over 550,000 with matched molecular data and outcomes, enables our team and research collaborators to better understand the biological hallmarks of cancers and how they impact clinical outcomes, paving the way for personalized therapies and improved patient outcomes,” said Caris President David Spetzler, MS, PhD, MBA. Learn more: https://lnkd.in/girNftdt #SABCS24

🌟 Join Us at the Breast Cancer Research and Therapeutics Summit (BCRTS-2025)! 🌟 Breast cancer remains one of the most prevalent cancers affecting women globally, significantly contributing to cancer diagnoses and mortality. To address this critical challenge, Arcs International is proud to host the Breast Cancer Research and Therapeutics Summit (BCRTS-2025) on March 21-22, 2025. 🧬 Theme: Advancing Breast Cancer Therapies: Innovations and Breakthroughs 🗓 Dates: March 21-22, 2025 💻 Location: Online/Virtual Conference 📢 Don't miss the opportunity to be part of this vital conversation and contribute to the advancement of breast cancer research. Together, we can pave the way for more effective treatments and improved outcomes for patients worldwide. #BreastCancerResearch #BCRTS2025 #BreastCancerAwareness #CancerTherapies #Immunotherapy #TargetedTherapies #PersonalizedMedicine #ScientificConference #CancerResearch

Join CURE, UW Carbone Cancer Center, Susan G Komen in Madison, WI on November 13 at 6:00 PM for CURE's Educated Patient® Updates in Metastatic Breast Cancer. Hear from breast cancer experts and connect with patients, survivors, and caregivers. Knowledge you'll walk away with includes: • Understanding metastatic breast cancer and its subtypes • Initial hormone therapy for treatment of ER+/HER2- metastatic breast cancer • Biomarkers: What they are and why we test for them • Next hormone therapy for ER+/HER2- metastatic breast cancer that progresses or stops responding • A hypothetical example of a patient’s treatment strategy Reserve your seat today! https://ow.ly/W4tX50TL3TN

🌟 Join Us at the Breast Cancer Research and Therapeutics Summit (BCRTS-2025)! 🌟 Breast cancer remains one of the most prevalent cancers affecting women globally, significantly contributing to cancer diagnoses and mortality. To address this critical challenge, Arcs International is proud to host the Breast Cancer Research and Therapeutics Summit (BCRTS-2025) on March 21-22, 2025. 🧬 Theme: Advancing Breast Cancer Therapies: Innovations and Breakthroughs 🗓 Dates: March 21-22, 2025 💻 Location: Online/Virtual Conference 📢 Don't miss the opportunity to be part of this vital conversation and contribute to the advancement of breast cancer research. Together, we can pave the way for more effective treatments and improved outcomes for patients worldwide. #BreastCancerResearch #BCRTS2025 #BreastCancerAwareness #CancerTherapies #Immunotherapy #TargetedTherapies #PersonalizedMedicine #ScientificConference #CancerResearch

#PublicationAlert Advancing the Field of HER2+ Breast Cancer Treatment: MarksMan Medical Writing Team Scores Again with a New Publication on BP02, a Promising Trastuzumab Biosimilar. This latest publication delves into the efficacy and safety of BP02 for HER2+ metastatic breast cancer patients. It compares BP02 to the established treatment (reference trastuzumab, RT: Herceptin®-EU) through a phase III clinical trial. The trial demonstrated equivalent objective response rates and similar safety profiles between BP02 and Herceptin®, highlighting the potential cost-effectiveness of BP02 as a biosimilar alternative. This research has the potential to significantly impact the HER2+ breast cancer treatment landscape by offering a potentially more accessible therapeutic option. Read the full publication here: https://lnkd.in/gWAJ5zRS #MarksManHealthcare #BreastCancer #HER2Positive #Biosimilars #MedicalWriting

In South Africa, an estimated 19.4 million women aged 15 years and older are at risk of developing breast cancer. Moreover, breast cancer is a leading cause of death among South African women. At Novartis, we endeavor to transform breast cancer care by continuing to deliver treatment that extends and improve the lives of those with metastatic breast cancer and advance research into early breast cancer therapy options. #NovartisSA #ReimaginingMedicine #BreastCancer #Oncology #CancerResearch Fuse Approval FA-11268427 Approval date: 29 September 2024 Expiry Date: 29 September 2026

September is Prostate Cancer Awareness Month! 🎗️💙 Prostate cancer is one of the most common cancers among men, and this month serves as a crucial reminder of the importance of early detection, awareness, and research. At the OPTIMA Project, we are committed to advancing research and innovation in prostate cancer care. Our work is focused on improving the diagnosis, treatment, and management of prostate cancer, striving to offer better care and outcomes for those affected by this disease. Join us in supporting Prostate Cancer Awareness Month by spreading the word, encouraging regular check-ups, and advocating for continued research. Together, we can make a difference in the lives of prostate cancer patients. #ProstateCancerAwareness #OPTIMAProject #HealthcareInnovation #CancerResearch #PatientCare Check out our website to find out more. https://buff.ly/3YQsdOM

In a recent study, researchers investigated the efficacy of sequential antibody-drug conjugate (ADC) therapy in metastatic breast cancer, specifically focusing on the use of sacituzumab govitecan (SG) and trastuzumab deruxtecan (TDXd). Modest clinical activity of both SG and TDXd when used as second-line ADC therapy (ADC2) in heavily pre-treated patients. The study highlighted that the treatment line at the time of ADC2 significantly influenced PFS, with later treatment lines correlating with shorter PFS. Moreover, the study emphasized the need for further research to explore the potential implications of payload cross-resistance, which could potentially undermine the benefits of sequential ADC therapy in metastatic breast cancer. This call for additional studies underscores the complexity of treatment strategies in advanced breast cancer and the importance of optimizing therapeutic approaches to improve patient outcomes. Read More https://lnkd.in/dzNWySZv #BreastCancerResearch #ADCTherapy #RealWorldOutcomes #PatientOutcomes #CancerTreatment

October is Breast Cancer Awareness Month! At MMS, we are deeply committed to the fight against breast cancer. As a global leader in oncology drug development, we understand the critical role that innovation and research play in bringing new, effective therapies to patients in need. Breast cancer affects millions of lives each year, and our experts collaborate closely with sponsors to support the submission of new oncology treatments to global health authorities. This month, we stand united with survivors, fighters, and their loved ones, raising awareness and supporting ongoing research. Together, we can continue to push boundaries, innovate, and strive for a future where breast cancer is a thing of the past. #BreastCancerAwareness #Oncology #CancerResearch #DrugDevelopment #ClinicalResearch #OneMMS